Icaridin (Picaridin) Insect Repellent Market Size, Trends & Growth Opportunity By Product Formulation (Spray, Lotion, Gel), By Active Ingredient Concentration (Low, Mid-Range, High-Duration), By Application (Household, Travel, Industrial), By End User (Retail Consumers, Government Health Agencies), By Region and Forecast Till 2030

Report ID : AMR1005847 | Industries : Consumer Goods | Published On :August 2026 | Page Count : 227

Request Sample
Ask for Customization

The icaridin (picaridin) insect repellent market covers the spray, lotion, gel, aerosol, roll-on and wipe-based formulations that retail consumers, government health agencies, hospitals and industrial workforce operators rely on for mosquito and insect protection across Latin America's tropical and subtropical zones.

This market occupies a distinct and growing position within the region's broader personal care and public health supply chain, valued for its role in both everyday consumer protection and institutional vector-control response to dengue, Zika, chikungunya and malaria.

Brazil anchors regional demand for this report's scope, with high-incidence demand concentrated across Sao Paulo, Campinas, Curitiba, Porto Alegre and Belo Horizonte alongside the states of Parana, Santa Catarina, Rio Grande do Sul and Minas Gerais, supported by significant demand from Mexico, Argentina, Chile, Colombia and Peru.

The market spans a wide range of product formulations, active ingredient concentrations, applications and end users, from individual retail consumers seeking dermatologically safe household protection to government health agencies running large-scale institutional procurement programs during disease outbreak periods.

Buyer sophistication continues to rise across this market, with both consumer and institutional buyers increasingly evaluating repellents not just on price but on dermatological safety, protection duration and regulatory classification credentials.

As a category, icaridin repellents sit at the intersection of consumer personal care and public health preparedness, a combination that has made formulation and concentration selection an increasingly strategic consideration within the region's broader vector-borne disease prevention agenda.

Product development across the region has shifted meaningfully over the past decade, with manufacturers increasingly prioritizing dermatological safety and formulation transparency over price alone as the primary consumer purchasing driver.

Regulatory attention on active ingredient classification and labeling accuracy has intensified across nearly every producing country, pushing manufacturers toward more rigorous compliance documentation even where enforcement has historically been inconsistent.

Investment in this category is increasingly framed by consumer goods manufacturers as a strategic public-health-adjacent opportunity rather than a routine seasonal product line, given how directly repellent demand tracks the region's disease-burden trajectory.

Market Size & Growth Forecast (2026 to 2030)

The icaridin (picaridin) insect repellent market across Latin America is estimated at approximately USD 550 Million in 2025 and is projected to reach approximately USD 825 Million by 2030, expanding at a compound annual growth rate of roughly 8.4 percent across the forecast period, reflecting sustained consumer demand alongside expanding institutional vector-control procurement.

This growth trajectory reflects continued substitution toward icaridin from older active ingredients, particularly among dermatologically sensitive consumer segments and pediatric-focused buyers seeking a gentler alternative to traditional DEET-based repellents.

High-duration protection formulations are expected to grow fastest across the forecast period, as both outdoor recreational users and industrial workforce operators increasingly prioritize longer-lasting protection over frequent reapplication.

Country-level growth rates vary meaningfully within this overall figure, with Brazil expected to post the highest regional CAGR given its outsized disease burden, while smaller markets like Chile and Argentina grow more steadily off a lower base.

MetricValue
Market Size (2025)Approximately USD 550 Million
Forecast Size (2030)Approximately USD 825 Million
CAGR (2025-2030)Approximately 8.4%
Base Year2025
Forecast Period2026-2030 (5-year)
Largest Formulation TypeSpray repellents
Fastest-Growing SegmentHigh-duration protection formulations
Leading Regional Demand CenterBrazil (Sao Paulo, Rio Grande do Sul, Minas Gerais)
Key Growth DriverDengue, Zika and chikungunya outbreak-driven demand and institutional procurement
Market StructureMixed, with global consumer majors and Brazilian pharmaceutical groups

Market Drivers

Rising incidence of dengue, Zika, chikungunya and malaria across Brazil and neighboring countries, sustaining both consumer and institutional demand for effective, dermatologically safe repellent protection.

Growing government mosquito-control procurement programs across Latin America, with public health agencies increasingly specifying icaridin-based formulations for large-scale distribution campaigns.

Increasing consumer preference for dermatologically safe, pediatric-appropriate repellents, favoring icaridin over older active ingredients associated with skin irritation and stronger odor.

Expanding tourism and outdoor recreational activity across the region's tropical destinations, sustaining travel-protection demand alongside everyday household use.

Rising industrial and occupational safety requirements in outdoor and agricultural workforce settings, particularly across Brazil's industrial workforce concentration hubs.

Continued e-commerce channel expansion, broadening consumer access to premium and specialty repellent formulations beyond traditional pharmacy and supermarket distribution.

Growing consumer and retailer demand for transparent formulation disclosure, pushing manufacturers to document active ingredient sourcing and testing practices across the full product line.

Growing international travel to and within the region has also created secondary demand from foreign visitors seeking locally available, regulation-compliant repellent products upon arrival.

Growing collaboration between manufacturers and public health authorities on joint awareness campaigns has further reinforced consumer trust in icaridin as an effective, dermatologically gentle protection option.

Market Restraints

Higher per-unit cost of icaridin formulations relative to older active ingredients, which remains a barrier for price-sensitive retail consumers in several secondary markets.

Distribution inefficiencies across secondary Latin American markets outside major urban centers, limiting consistent product availability in some tourism-heavy and rural high-incidence regions.

Counterfeit and substandard product risks in several markets, which can undermine consumer trust in genuine icaridin-labeled formulations.

Facility budget cycles that do not align with a vendor's fiscal calendar can further complicate institutional procurement timing, occasionally delaying large-scale government tenders by a full budget cycle.

Skilled formulation and regulatory affairs talent availability constraints, as compliant biocide-regulated product development requires expertise that remains in comparatively short supply across several producing countries.

Seasonal demand volatility tied to mosquito activity cycles, which can complicate manufacturing and inventory planning relative to more consistently demanded personal care categories.

Import duty and currency volatility across several producing countries can complicate cross-border active ingredient sourcing and finished-product distribution, adding a further cost dimension manufacturers must manage.

Retail shelf space competition from established DEET and natural-ingredient repellent brands can also slow icaridin adoption in certain price-sensitive market segments.

Market Opportunities

Considerable untapped opportunity in premium, long-duration repellent formulations, as both consumer and institutional buyers increasingly prioritize protection duration over price alone.

Underserved pediatric-safe offerings, providing manufacturers a clear differentiation path given rising parental demand for dermatologically gentle formulations.

Underserved institutional procurement segments outside Brazil's largest urban centers, particularly across Colombia, Peru and secondary Mexican and Argentine markets.

Opportunities in industrial and occupational repellent programs, an application category that remains comparatively underdeveloped relative to consumer retail demand.

Emerging demand for eco-conscious and skin-safe formulation innovation, reflecting broader consumer sustainability preferences extending into the personal care category.

Growing opportunity in digital consumer education platforms, as buyers increasingly seek verifiable information on formulation safety and protection duration before purchase.

Opportunity also exists in combination products pairing repellent function with sunscreen or basic skincare benefit, appealing to consumers seeking simplified daily outdoor-protection routines.

Product Formulations and Active Ingredient Concentrations

The market spans spray, lotion, gel, aerosol, roll-on and wipe-based formulations, each paired with low, mid-range, high-duration or pediatric-safe active ingredient concentration tiers. Full segmentation detail is covered on the icaridin repellent product formulations and active ingredient concentrations page.

Applications and End Users

Household mosquito protection, outdoor and recreational use, travel protection, military and defense, industrial and occupational safety, healthcare and hospital use, and emergency outbreak response each connect to distinct end users spanning retail consumers, families, travelers, government health agencies, hospitals and industrial workforce operators. The full breakdown appears on the icaridin repellent applications and end users page.

Distribution Channels and Packaging Types

Supermarkets, hypermarkets, pharmacies, e-commerce platforms, direct distributors, institutional procurement contracts and specialty outdoor retailers each connect to distinct packaging types spanning small-format personal use, family-size, institutional bulk and travel-size portable packaging. Full distribution and packaging detail is covered on the icaridin repellent distribution channels and packaging types page.

Regulatory Classification and Business Models

Cosmetic-grade formulations, biocide-regulated products and pharmaceutical-adjacent repellent formulations each connect to distinct business models spanning branded consumer products, private-label manufacturing, contract manufacturing and active ingredient supply partnerships. Full detail is covered on the icaridin repellent regulatory classification and business models page.

Icaridina Repellent Market, By Region

Brazil, anchored by Sao Paulo, Campinas, Curitiba, Porto Alegre and Belo Horizonte across the states of Parana, Santa Catarina, Rio Grande do Sul and Minas Gerais, represents the market's largest and most concentrated regional demand center, reflecting its high dengue, Zika and chikungunya disease burden.

Mexico and Colombia together represent the market's second-largest demand cluster, driven by significant tropical and subtropical urban populations alongside growing government mosquito-control procurement activity.

Argentina, Chile and Peru each represent smaller but steadily growing regional demand centers, reflecting expanding tourism activity and rising consumer awareness of dermatologically safe repellent options across these markets.

Central American and Caribbean demand, while smaller in absolute volume than the six core countries this report tracks, represents a further area of growing interest given rising regional tourism and disease-prevention awareness.

Leading Icaridin Repellent Companies

SC Johnson, Reckitt, Bayer, Beiersdorf, Laboratorio Catarinense, Cimed, Hypera Pharma, Osler do Brasil, Nutriex, Gojo Industries, Sawyer Products, Godrej Consumer Products, Henlau Quimica, 3M and Ecolab together shape the market's competitive landscape. A full, non-ranked overview of the companies leading the icaridin repellent market is available on our companies page.

Beyond This Page

Consumer goods manufacturers, distributors and institutional buyers making a market-entry, expansion or procurement decision on the strength of the public segmentation covered on these pages alone are working from directional signal rather than decision-grade detail. Category-level description of formulations, applications and buyer structure explains the shape of this market, but it does not tell a manufacturer which specific named competitor holds the strongest institutional relationships in a given country, what a comparable government tender is actually priced at, or how a specific end user moves through its own procurement cycle, the detail an expansion or procurement decision genuinely depends on.

That gap has real consequences at the point a manufacturer or distributor commits capital to this market. Without the buyer intelligence, competitive benchmarking and company-level profiles the full report adds, a decision-maker is left choosing which formulation to invest in, which country to prioritize, or which distribution channel to pursue on category-level description alone, a considerably weaker basis for that decision than the underlying report data provides.

Manufacturers and distributors proceeding on directional signal alone risk misallocating capital toward the wrong formulation, country or channel relative to what a fully informed, data-backed decision would support.

The full report additionally profiles company-level financial indicators, recent product launch announcements and institutional supply agreement activity that this summary page does not attempt to reproduce.

Frequently Asked Questions

The market across Latin America is estimated at approximately USD 550 million in 2025 and is projected to reach approximately USD 825 million by 2030, growing at around 8.4 percent annually.

Rising dengue, Zika and chikungunya incidence, growing government mosquito-control procurement, and increasing consumer preference for dermatologically safe repellents are the primary drivers.

Icaridin (also known as picaridin) is generally regarded as gentler on skin with less odor than DEET, making it a preferred option for pediatric and dermatologically sensitive users.

SC Johnson, Reckitt, Bayer and Beiersdorf are among the leading global consumer majors, alongside Brazilian groups including Laboratorio Catarinense, Cimed and Hypera Pharma.

Brazil leads regional demand given its high dengue and Zika disease burden, followed by Mexico and Colombia, with growing activity in Argentina, Chile and Peru.

Inquire Before Buying Request Free Sample Ask For Discount

1. Introduction

1.1. Objective of the Study

1.2. Market Definition

1.3. Market Scope

2. Executive Summary

3. Icaridin (Picaridin) Insect Repellent Market - Latin America Focused View with Spotlight on Brazil-Based Consumer, Institutional and Industrial Applications Market Analysis and Forecast (2026–2030)

3.1. Overview

3.2. Market Dynamics

3.3. Drivers

3.4. Restraints

3.5. Opportunities

3.6. Porter's Five Forces Model

3.7. Value Chain Analysis

4. Icaridin (Picaridin) Insect Repellent Market - Latin America Focused View with Spotlight on Brazil-Based Consumer, Institutional and Industrial Applications, By Product Formulation

4.1. Spray Repellents

4.2. Lotion and Cream Formulations

4.3. Gel-Based Repellents

4.4. Aerosol Repellents

4.5. Roll-on Repellents

4.6. Wet Wipes and Portable Applications

4.7. Concentrated Active Ingredient Formulations

5. Icaridin (Picaridin) Insect Repellent Market - Latin America Focused View with Spotlight on Brazil-Based Consumer, Institutional and Industrial Applications, By Active Ingredient Concentration

5.1. Low Concentration Formulations

5.2. Mid-Range Protection Formulations

5.3. High-Duration Protection Formulations

5.4. Pediatric-Safe Concentration Categories

6. Icaridin (Picaridin) Insect Repellent Market - Latin America Focused View with Spotlight on Brazil-Based Consumer, Institutional and Industrial Applications, By Application

6.1. Household Mosquito Protection

6.2. Outdoor and Recreational Use

6.3. Travel Protection

6.4. Military and Defense Applications

6.5. Industrial and Occupational Safety Use

6.6. Healthcare and Hospital Use

6.7. Emergency Outbreak Response Programs

7. Icaridin (Picaridin) Insect Repellent Market - Latin America Focused View with Spotlight on Brazil-Based Consumer, Institutional and Industrial Applications, By End User

7.1. Retail Consumers

7.2. Families and Pediatric Users

7.3. Travelers

7.4. Government Health Agencies

7.5. Hospitals and Clinics

7.6. Industrial Workforce Operators

7.7. Hospitality and Tourism Operators

8. Icaridin (Picaridin) Insect Repellent Market - Latin America Focused View with Spotlight on Brazil-Based Consumer, Institutional and Industrial Applications, By Distribution Channel

8.1. Supermarkets and Hypermarkets

8.2. Pharmacies and Drugstores

8.3. E-Commerce Platforms

8.4. Direct Distributors

8.5. Institutional Procurement Contracts

8.6. Specialty Outdoor Retailers

9. Icaridin (Picaridin) Insect Repellent Market - Latin America Focused View with Spotlight on Brazil-Based Consumer, Institutional and Industrial Applications, By Packaging Type

9.1. Small-Format Personal Use Packaging

9.2. Family-Size Packaging

9.3. Institutional Bulk Packaging

9.4. Travel-Size Portable Packaging

10. Icaridin (Picaridin) Insect Repellent Market - Latin America Focused View with Spotlight on Brazil-Based Consumer, Institutional and Industrial Applications, By Regulatory Classification

10.1. Cosmetic-Grade Formulations

10.2. Biocide-Regulated Products

10.3. Pharmaceutical-Adjacent Repellent Formulations

11. Icaridin (Picaridin) Insect Repellent Market - Latin America Focused View with Spotlight on Brazil-Based Consumer, Institutional and Industrial Applications, By Business Model

11.1. Branded Consumer Products

11.2. Private-Label Manufacturing

11.3. Contract Manufacturing

11.4. Active Ingredient Supply Partnerships

12. Buyer Intelligence & Demand Landscape

12.1. Buyer Segmentation by Institutional and Retail Purchasing Behavior

12.2. Consumer Demand Evolution for Dermatologically Safe Repellents

12.3. Government Mosquito-Control Procurement Ecosystem

12.4. Hospital and Healthcare Buyer Mapping

12.5. Industrial Workforce Protection Demand

12.6. Travel and Tourism-Related Purchasing Behavior

12.7. Country-Wise Buyer Demand Assessment

12.8. Regional Distributor and Importer Ecosystem

12.9. Procurement Models Across Retail and Institutional Channels

12.10. Key Buying Triggers During Dengue, Zika, Chikungunya, and Malaria Outbreaks

12.11. Decision-Maker Roles Across Healthcare and Retail Channels

12.12. Budget Ownership Structures Within Institutional Procurement

12.13. Vendor Evaluation Criteria

12.14. Contract Value Bands Across Public and Private Buyers

12.15. Seasonal Procurement Cycles and Replenishment Behavior

12.16. Strategic Relevance for Henlau Quimica's Formulation and Distribution Activities

13. Latin America Market Analysis and Forecast (2026–2030)

13.1. Introduction

13.2. Market Share Analysis

13.3. Market Size and Forecast

13.4. Market Size and Forecast, By Geography

13.4.1. Brazil

13.4.1.1. Market Share Analysis

13.4.1.2. Market Size and Forecast

13.4.1.3. By Product

13.4.1.4. By Technology

13.4.1.5. By Application

13.4.1.6. By Customer

13.4.1.7. Sao Paulo

13.4.1.7.1. Market Share Analysis

13.4.1.7.2. Market Size and Forecast

13.4.1.7.3. By Product

13.4.1.7.4. By Technology

13.4.1.7.5. By Application

13.4.1.7.6. By Customer

13.4.1.8. Campinas

13.4.1.8.1. Market Share Analysis

13.4.1.8.2. Market Size and Forecast

13.4.1.8.3. By Product

13.4.1.8.4. By Technology

13.4.1.8.5. By Application

13.4.1.8.6. By Customer

13.4.1.9. Curitiba

13.4.1.9.1. Market Share Analysis

13.4.1.9.2. Market Size and Forecast

13.4.1.9.3. By Product

13.4.1.9.4. By Technology

13.4.1.9.5. By Application

13.4.1.9.6. By Customer

13.4.1.10. Porto Alegre

13.4.1.10.1. Market Share Analysis

13.4.1.10.2. Market Size and Forecast

13.4.1.10.3. By Product

13.4.1.10.4. By Technology

13.4.1.10.5. By Application

13.4.1.10.6. By Customer

13.4.1.11. Belo Horizonte

13.4.1.11.1. Market Share Analysis

13.4.1.11.2. Market Size and Forecast

13.4.1.11.3. By Product

13.4.1.11.4. By Technology

13.4.1.11.5. By Application

13.4.1.11.6. By Customer

13.4.1.12. Parana

13.4.1.12.1. Market Share Analysis

13.4.1.12.2. Market Size and Forecast

13.4.1.12.3. By Product

13.4.1.12.4. By Technology

13.4.1.12.5. By Application

13.4.1.12.6. By Customer

13.4.1.13. Santa Catarina

13.4.1.13.1. Market Share Analysis

13.4.1.13.2. Market Size and Forecast

13.4.1.13.3. By Product

13.4.1.13.4. By Technology

13.4.1.13.5. By Application

13.4.1.13.6. By Customer

13.4.1.14. Rio Grande Do Sul

13.4.1.14.1. Market Share Analysis

13.4.1.14.2. Market Size and Forecast

13.4.1.14.3. By Product

13.4.1.14.4. By Technology

13.4.1.14.5. By Application

13.4.1.14.6. By Customer

13.4.1.15. Minas Gerais

13.4.1.15.1. Market Share Analysis

13.4.1.15.2. Market Size and Forecast

13.4.1.15.3. By Product

13.4.1.15.4. By Technology

13.4.1.15.5. By Application

13.4.1.15.6. By Customer

13.4.2. Mexico

13.4.2.1. Market Share Analysis

13.4.2.2. Market Size and Forecast

13.4.2.3. By Product

13.4.2.4. By Technology

13.4.2.5. By Application

13.4.2.6. By Customer

13.4.3. Argentina

13.4.3.1. Market Share Analysis

13.4.3.2. Market Size and Forecast

13.4.3.3. By Product

13.4.3.4. By Technology

13.4.3.5. By Application

13.4.3.6. By Customer

13.4.4. Chile

13.4.4.1. Market Share Analysis

13.4.4.2. Market Size and Forecast

13.4.4.3. By Product

13.4.4.4. By Technology

13.4.4.5. By Application

13.4.4.6. By Customer

13.4.5. Colombia

13.4.5.1. Market Share Analysis

13.4.5.2. Market Size and Forecast

13.4.5.3. By Product

13.4.5.4. By Technology

13.4.5.5. By Application

13.4.5.6. By Customer

13.4.6. Peru

13.4.6.1. Market Share Analysis

13.4.6.2. Market Size and Forecast

13.4.6.3. By Product

13.4.6.4. By Technology

13.4.6.5. By Application

13.4.6.6. By Customer

14. Competition Analysis

14.1. Market Positioning Overview

14.1.1. Global vs Regional Insect Repellent Manufacturers

14.1.2. Latin American Formulation Specialists

14.1.3. Pricing and Value Positioning Analysis

14.1.4. Dermatological Safety Differentiation

14.1.5. Long-Duration Protection Positioning

14.1.6. Pediatric-Safe Branding Strategies

14.1.7. Institutional Versus Retail-Focused Positioning

14.2. Competitive Benchmarking Metrics

14.2.1. Estimated Market Positioning

14.2.2. Product Portfolio Breadth

14.2.3. Distribution and Retail Penetration

14.2.4. Pharmacy Channel Strength

14.2.5. Institutional Procurement Capabilities

14.2.6. Brand Visibility and Consumer Trust

14.2.7. Regulatory Compliance and Certifications

14.2.8. Innovation Capabilities

14.2.9. Manufacturing and Sourcing Footprint

14.3. Strategic Moves

14.3.1. New Repellent Product Launches

14.3.2. Expansion into Tropical Disease Prevention Categories

14.3.3. Distribution Partnerships in Latin America

14.3.4. E-Commerce Expansion Initiatives

14.3.5. Investments in Skin-Safe and Eco-Conscious Formulations

14.3.6. Institutional Supply Agreements

14.3.7. Regional Manufacturing Expansion

14.4. Competitive Mapping & Gaps

14.4.1. White-Space Opportunities in Premium Repellents

14.4.2. Gaps in Pediatric-Safe Offerings

14.4.3. Underserved Institutional Procurement Segments

14.4.4. Distribution Inefficiencies Across Secondary Latin American Markets

14.4.5. Opportunities in Industrial and Occupational Repellent Programs

14.4.6. Areas for Differentiation Through Formulation Innovation

15. Company Profiles

15.1. SC Johnson

15.1.1. Company Overview

15.1.2. Headquarters

15.1.3. Ownership Structure

15.1.4. Founding Year

15.1.5. Workforce Estimate

15.1.6. Geographic Footprint

15.1.7. Product and Formulation Portfolio

15.1.8. Target Customer Segments

15.1.9. Distribution and GTM Strategy

15.1.10. Retail and Institutional Channel Presence

15.1.11. Key Financial Indicators

15.1.12. Certifications and Compliance

15.1.13. Partnerships and Alliances

15.1.14. R&D and Formulation Innovation

15.1.15. Recent Developments

15.1.16. SWOT Analysis Snapshot

15.2. Reckitt

15.2.1. Company Overview

15.2.2. Headquarters

15.2.3. Ownership Structure

15.2.4. Founding Year

15.2.5. Workforce Estimate

15.2.6. Geographic Footprint

15.2.7. Product and Formulation Portfolio

15.2.8. Target Customer Segments

15.2.9. Distribution and GTM Strategy

15.2.10. Retail and Institutional Channel Presence

15.2.11. Key Financial Indicators

15.2.12. Certifications and Compliance

15.2.13. Partnerships and Alliances

15.2.14. R&D and Formulation Innovation

15.2.15. Recent Developments

15.2.16. SWOT Analysis Snapshot

15.3. Bayer

15.3.1. Company Overview

15.3.2. Headquarters

15.3.3. Ownership Structure

15.3.4. Founding Year

15.3.5. Workforce Estimate

15.3.6. Geographic Footprint

15.3.7. Product and Formulation Portfolio

15.3.8. Target Customer Segments

15.3.9. Distribution and GTM Strategy

15.3.10. Retail and Institutional Channel Presence

15.3.11. Key Financial Indicators

15.3.12. Certifications and Compliance

15.3.13. Partnerships and Alliances

15.3.14. R&D and Formulation Innovation

15.3.15. Recent Developments

15.3.16. SWOT Analysis Snapshot

15.4. Beiersdorf

15.4.1. Company Overview

15.4.2. Headquarters

15.4.3. Ownership Structure

15.4.4. Founding Year

15.4.5. Workforce Estimate

15.4.6. Geographic Footprint

15.4.7. Product and Formulation Portfolio

15.4.8. Target Customer Segments

15.4.9. Distribution and GTM Strategy

15.4.10. Retail and Institutional Channel Presence

15.4.11. Key Financial Indicators

15.4.12. Certifications and Compliance

15.4.13. Partnerships and Alliances

15.4.14. R&D and Formulation Innovation

15.4.15. Recent Developments

15.4.16. SWOT Analysis Snapshot

15.5. Laboratorio Catarinense

15.5.1. Company Overview

15.5.2. Headquarters

15.5.3. Ownership Structure

15.5.4. Founding Year

15.5.5. Workforce Estimate

15.5.6. Geographic Footprint

15.5.7. Product and Formulation Portfolio

15.5.8. Target Customer Segments

15.5.9. Distribution and GTM Strategy

15.5.10. Retail and Institutional Channel Presence

15.5.11. Key Financial Indicators

15.5.12. Certifications and Compliance

15.5.13. Partnerships and Alliances

15.5.14. R&D and Formulation Innovation

15.5.15. Recent Developments

15.5.16. SWOT Analysis Snapshot

15.6. Cimed

15.6.1. Company Overview

15.6.2. Headquarters

15.6.3. Ownership Structure

15.6.4. Founding Year

15.6.5. Workforce Estimate

15.6.6. Geographic Footprint

15.6.7. Product and Formulation Portfolio

15.6.8. Target Customer Segments

15.6.9. Distribution and GTM Strategy

15.6.10. Retail and Institutional Channel Presence

15.6.11. Key Financial Indicators

15.6.12. Certifications and Compliance

15.6.13. Partnerships and Alliances

15.6.14. R&D and Formulation Innovation

15.6.15. Recent Developments

15.6.16. SWOT Analysis Snapshot

15.7. Hypera Pharma

15.7.1. Company Overview

15.7.2. Headquarters

15.7.3. Ownership Structure

15.7.4. Founding Year

15.7.5. Workforce Estimate

15.7.6. Geographic Footprint

15.7.7. Product and Formulation Portfolio

15.7.8. Target Customer Segments

15.7.9. Distribution and GTM Strategy

15.7.10. Retail and Institutional Channel Presence

15.7.11. Key Financial Indicators

15.7.12. Certifications and Compliance

15.7.13. Partnerships and Alliances

15.7.14. R&D and Formulation Innovation

15.7.15. Recent Developments

15.7.16. SWOT Analysis Snapshot

15.8. Osler do Brasil

15.8.1. Company Overview

15.8.2. Headquarters

15.8.3. Ownership Structure

15.8.4. Founding Year

15.8.5. Workforce Estimate

15.8.6. Geographic Footprint

15.8.7. Product and Formulation Portfolio

15.8.8. Target Customer Segments

15.8.9. Distribution and GTM Strategy

15.8.10. Retail and Institutional Channel Presence

15.8.11. Key Financial Indicators

15.8.12. Certifications and Compliance

15.8.13. Partnerships and Alliances

15.8.14. R&D and Formulation Innovation

15.8.15. Recent Developments

15.8.16. SWOT Analysis Snapshot

15.9. Nutriex

15.9.1. Company Overview

15.9.2. Headquarters

15.9.3. Ownership Structure

15.9.4. Founding Year

15.9.5. Workforce Estimate

15.9.6. Geographic Footprint

15.9.7. Product and Formulation Portfolio

15.9.8. Target Customer Segments

15.9.9. Distribution and GTM Strategy

15.9.10. Retail and Institutional Channel Presence

15.9.11. Key Financial Indicators

15.9.12. Certifications and Compliance

15.9.13. Partnerships and Alliances

15.9.14. R&D and Formulation Innovation

15.9.15. Recent Developments

15.9.16. SWOT Analysis Snapshot

15.10. Gojo Industries

15.10.1. Company Overview

15.10.2. Headquarters

15.10.3. Ownership Structure

15.10.4. Founding Year

15.10.5. Workforce Estimate

15.10.6. Geographic Footprint

15.10.7. Product and Formulation Portfolio

15.10.8. Target Customer Segments

15.10.9. Distribution and GTM Strategy

15.10.10. Retail and Institutional Channel Presence

15.10.11. Key Financial Indicators

15.10.12. Certifications and Compliance

15.10.13. Partnerships and Alliances

15.10.14. R&D and Formulation Innovation

15.10.15. Recent Developments

15.10.16. SWOT Analysis Snapshot

15.11. Sawyer Products

15.11.1. Company Overview

15.11.2. Headquarters

15.11.3. Ownership Structure

15.11.4. Founding Year

15.11.5. Workforce Estimate

15.11.6. Geographic Footprint

15.11.7. Product and Formulation Portfolio

15.11.8. Target Customer Segments

15.11.9. Distribution and GTM Strategy

15.11.10. Retail and Institutional Channel Presence

15.11.11. Key Financial Indicators

15.11.12. Certifications and Compliance

15.11.13. Partnerships and Alliances

15.11.14. R&D and Formulation Innovation

15.11.15. Recent Developments

15.11.16. SWOT Analysis Snapshot

15.12. Godrej Consumer Products

15.12.1. Company Overview

15.12.2. Headquarters

15.12.3. Ownership Structure

15.12.4. Founding Year

15.12.5. Workforce Estimate

15.12.6. Geographic Footprint

15.12.7. Product and Formulation Portfolio

15.12.8. Target Customer Segments

15.12.9. Distribution and GTM Strategy

15.12.10. Retail and Institutional Channel Presence

15.12.11. Key Financial Indicators

15.12.12. Certifications and Compliance

15.12.13. Partnerships and Alliances

15.12.14. R&D and Formulation Innovation

15.12.15. Recent Developments

15.12.16. SWOT Analysis Snapshot

15.13. Henlau Quimica

15.13.1. Company Overview

15.13.2. Headquarters

15.13.3. Ownership Structure

15.13.4. Founding Year

15.13.5. Workforce Estimate

15.13.6. Geographic Footprint

15.13.7. Product and Formulation Portfolio

15.13.8. Target Customer Segments

15.13.9. Distribution and GTM Strategy

15.13.10. Retail and Institutional Channel Presence

15.13.11. Key Financial Indicators

15.13.12. Certifications and Compliance

15.13.13. Partnerships and Alliances

15.13.14. R&D and Formulation Innovation

15.13.15. Recent Developments

15.13.16. SWOT Analysis Snapshot

15.14. 3M

15.14.1. Company Overview

15.14.2. Headquarters

15.14.3. Ownership Structure

15.14.4. Founding Year

15.14.5. Workforce Estimate

15.14.6. Geographic Footprint

15.14.7. Product and Formulation Portfolio

15.14.8. Target Customer Segments

15.14.9. Distribution and GTM Strategy

15.14.10. Retail and Institutional Channel Presence

15.14.11. Key Financial Indicators

15.14.12. Certifications and Compliance

15.14.13. Partnerships and Alliances

15.14.14. R&D and Formulation Innovation

15.14.15. Recent Developments

15.14.16. SWOT Analysis Snapshot

15.15. Ecolab

15.15.1. Company Overview

15.15.2. Headquarters

15.15.3. Ownership Structure

15.15.4. Founding Year

15.15.5. Workforce Estimate

15.15.6. Geographic Footprint

15.15.7. Product and Formulation Portfolio

15.15.8. Target Customer Segments

15.15.9. Distribution and GTM Strategy

15.15.10. Retail and Institutional Channel Presence

15.15.11. Key Financial Indicators

15.15.12. Certifications and Compliance

15.15.13. Partnerships and Alliances

15.15.14. R&D and Formulation Innovation

15.15.15. Recent Developments

15.15.16. SWOT Analysis Snapshot

Frequently Asked Questions

The market across Latin America is estimated at approximately USD 550 million in 2025 and is projected to reach approximately USD 825 million by 2030, growing at around 8.4 percent annually.

Rising dengue, Zika and chikungunya incidence, growing government mosquito-control procurement, and increasing consumer preference for dermatologically safe repellents are the primary drivers.

Icaridin (also known as picaridin) is generally regarded as gentler on skin with less odor than DEET, making it a preferred option for pediatric and dermatologically sensitive users.

SC Johnson, Reckitt, Bayer and Beiersdorf are among the leading global consumer majors, alongside Brazilian groups including Laboratorio Catarinense, Cimed and Hypera Pharma.

Brazil leads regional demand given its high dengue and Zika disease burden, followed by Mexico and Colombia, with growing activity in Argentina, Chile and Peru.

Inquire Before Buying Request Free Sample Ask For Discount

Public market anchors

The Latin America picaridin market, a direct match for this report's active-ingredient scope, was estimated at approximately USD 0.5 billion in 2024 and USD 0.55 billion in 2025 across public sources, projected to reach approximately USD 1.1 billion by 2033 at roughly 8.4% CAGR, with Brazil identified as the region's highest-growth single-country market.

Country-level cross-check

Brazil's overall insect repellent market (spanning all active ingredients, not icaridin alone) was independently estimated at approximately USD 215 million in 2024, growing to approximately USD 315 million by 2030 at roughly 6.4% CAGR, providing a directional cross-check consistent with icaridin specifically growing faster than the broader repellent category given its dermatological-safety positioning.

Base year derivation

The 2025 base estimate of approximately USD 550 million was taken directly from the Latin America picaridin-specific public estimate, requiring no additional scope adjustment given the close alignment between that category and this report's regional icaridin/picaridin scope.

Growth rate derivation

The forecast CAGR of approximately 8.4% matches the Latin America picaridin market's own public growth trajectory, reflecting sustained substitution toward icaridin from older active ingredients alongside expanding institutional vector-control procurement across the region.

Frequently Asked Questions

The market across Latin America is estimated at approximately USD 550 million in 2025 and is projected to reach approximately USD 825 million by 2030, growing at around 8.4 percent annually.

Rising dengue, Zika and chikungunya incidence, growing government mosquito-control procurement, and increasing consumer preference for dermatologically safe repellents are the primary drivers.

Icaridin (also known as picaridin) is generally regarded as gentler on skin with less odor than DEET, making it a preferred option for pediatric and dermatologically sensitive users.

SC Johnson, Reckitt, Bayer and Beiersdorf are among the leading global consumer majors, alongside Brazilian groups including Laboratorio Catarinense, Cimed and Hypera Pharma.

Brazil leads regional demand given its high dengue and Zika disease burden, followed by Mexico and Colombia, with growing activity in Argentina, Chile and Peru.

Inquire Before Buying Request Free Sample Ask For Discount